Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Description

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Conditions

Community-acquired Pneumonia, Influenza, COVID-19

Study Overview

Study Details

Study overview

REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic such as COVID-19. REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19 in the United States of America.

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Condition
Community-acquired Pneumonia, Influenza, COVID-19
Intervention / Treatment

-

Contacts and Locations

Jacksonville

University of Florida, Jacksonville, Florida, United States, 32209

Augusta

Augusta University, Augusta, Georgia, United States, 30912

Chicago

University of Illinois Health, Chicago, Illinois, United States, 60612

New Orleans

Tulane Medical Center, New Orleans, Louisiana, United States, 70112

Ann Arbor

University of Michigan, Ann Arbor, Michigan, United States, 48109

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Winston-Salem

Wake Forest Baptist Health, Winston-Salem, North Carolina, United States, 27157-1009

Columbus

The Ohio State University Wexner Medical Center, Columbus, Ohio, United States, 43210

Portland

Oregon Health and Science University, Portland, Oregon, United States, 97239-3098

Pittsburgh

University of Pittsburgh Medical Centre, Pittsburgh, Pennsylvania, United States,

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission with:
  • 1. symptoms or signs or both that are consistent with lower respiratory tract infection AND
  • 2. Radiological evidence of new onset consolidation (in patients with pre-existing radiological changes, evidence of new infiltrate)
  • 2. Up to 48 hours after ICU admission, receiving organ support with one or more of:
  • 1. Non-invasive or Invasive ventilatory support;
  • 2. Receiving infusion of vasopressor or inotropes or both
  • 1. Healthcare-associated pneumonia:
  • 1. Prior to this illness, is known to have been an inpatient in any healthcare facility within the last 30 days
  • 2. Resident of a nursing home or long term care facility
  • 2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  • 3. Previous participation in this REMAP within the last 90 days
  • 1. Adult patients (≥ 18 years) admitted to hospital with acute illness due to suspected or proven pandemic infection.
  • 1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
  • 2. Patient is expected to be discharged from hospital today or tomorrow
  • 3. More than 14 days have elapsed while admitted to hospital with symptoms of an acute illness due to suspected or proven pandemic infection.
  • 4. Previous participation in this REMAP within the last 90 days

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

UMC Utrecht,

Steve Webb, Prof, STUDY_CHAIR, Monash University, Study Chair REMAP-CAP Australia

Colin McArthur, Dr, STUDY_CHAIR, Medical Research Institute of New Zealand, Study Chair REMAP-CAP New Zealand

Marc Bonten, Prof, STUDY_CHAIR, UMC Utrecht, Study Chair REMAP-CAP Europe

Lennie Derde, MD, STUDY_CHAIR, UMC Utrecht, Coordinating Investigator REMAP-CAP Europe

John Marshall, Prof, STUDY_CHAIR, Unity Health Toronto, Study Chair REMAP-CAP Canada

Derek Angus, Prof, STUDY_CHAIR, University of Pittsburgh Medical Center, Study Chair REMAP-CAP USA

Study Record Dates

2028-02